Phase III clinical trials have revealed that the third-generation EGFR-TKI osimertinib provides a better progression-free survival (PFS) than platinum-based chemotherapy in NSCLC patients who have EGFR-T790M [6]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.